Objectives: This study aimed to update and validate a prediction rule for respiratory syncytial virus (RSV) hospitalization in preterm infants 33-35 weeks gestational age (WGA).
Study Design: The RISK study consisted of 2 multicenter prospective birth cohorts in 41 hospitals. Risk factors were assessed at birth among healthy preterm infants 33-35 WGA. All hospitalizations for respiratory tract infection were screened for proven RSV infection by immunofluorescence or polymerase chain reaction. Multivariate logistic regression analysis was used to update an existing prediction model in the derivation cohort (n = 1,227). In the validation cohort (n = 1,194), predicted versus actual RSV hospitalization rates were compared to determine validity of the model.
Results: RSV hospitalization risk in both cohorts was comparable (5.7% versus 4.9%). In the derivation cohort, a prediction rule to determine probability of RSV hospitalization was developed using 4 predictors: family atopy (OR 1.9; 95%CI, 1.1-3.2), birth period (OR 2.6; 1.6-4.2), breastfeeding (OR 1.7; 1.0-2.7) and siblings or daycare attendance (OR 4.7; 1.7-13.1). The model showed good discrimination (c-statistic 0.703; 0.64-0.76, 0.702 after bootstrapping). External validation showed good discrimination and calibration (c-statistic 0.678; 0.61-0.74).
Conclusions: Our prospectively validated prediction rule identifies infants at increased RSV hospitalization risk, who may benefit from targeted preventive interventions. This prediction rule can facilitate country-specific, cost-effective use of RSV prophylaxis in late preterm infants.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595233 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059161 | PLOS |
Andes Pediatr
August 2024
Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
Unlabelled: Palivizumab, a humanized monoclonal antibody against the respiratory syncytial virus (RSV), currently is indicated in groups at higher risk of developing severe RSV disease, such as extreme premature infants and patients with hemodynamically significant heart disease. In Chile, this strategy is guaranteed by Law 20850 (Ricarte Soto Law). Nevertheless, barriers to its administration included the need to transfer these labile patients and exposure to other users, with the risk of contagion in waiting rooms.
View Article and Find Full Text PDFPediatr Pulmonol
January 2025
Department of Pediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark.
Objective: To investigate the effect of viral co-infections on treatment length and treatment failure in children with lower respiratory tract infections (LRTI) supported with continuous positive airway pressure (CPAP) or high-flow nasal cannula oxygenation therapy (HFNC).
Methods: Patients aged 0-5 years hospitalized with viral LRTI and in need of respiratory support between August 1 and December 31, 2021, were retrospectively evaluated by patient chart audits.
Results: A total of 148 children (median age 10.
Messenger RNA (mRNA) therapeutics have garnered considerable attention due to their remarkable efficacy in the treatment of various diseases. The COVID-19 mRNA vaccine and RSV mRNA vaccine have been approved on the market. Due to the inherent nuclease-instability and negative charge of mRNA, delivery systems are developed to protect the mRNA from degradation and facilitate its crossing cell membrane to express functional proteins or peptides in the cytoplasm.
View Article and Find Full Text PDFJ Prev Med Hyg
September 2024
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Italy.
Acute respiratory infections (ARI) are a leading cause of global morbidity and mortality and they're primarily caused by viruses such as rhinovirus, coronavirus, and respiratory syncytial virus (RSV), and to a lesser extent by bacteria like Streptococcus pneumoniae and Mycoplasma pneumoniae. The study examines the impact of COVID-19 control measures on the circulation of respiratory pathogens, indicating a reduction in infections during the pandemic period. A retrospective study was conducted on 1,286 patients at the "G.
View Article and Find Full Text PDFOpen Forum Infect Dis
January 2025
Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
Background: Immunization against influenza and respiratory syncytial virus (RSV) protects pregnant individuals and their infants against infection via transplacental transport of immunoglobulin G (IgG). We sought to evaluate the quantity and efficiency of maternal influenza- and RSV-specific IgG transfer in pregnancies with preterm and full-term deliveries.
Methods: Delivery samples from 115 maternal-infant pairs (2018-2021) were analyzed for RSV prefusion F and IAV-H3 and IAV-H1 antibodies using electrochemiluminescence assays.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!